Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC8A1 | P32418 | 17/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4360142 | 0.92 | MEN1 (0.47) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4371021 | 0.89 | SLC8A1 (0.51) | SLC8A1 | |
| SCHEMBL4360588 | 0.89 | SLC8A1 (0.46) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4362568 | 0.87 | KDM4E (0.53) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4362221 | 0.85 | SLC8A1 (0.44) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4358846 | 0.85 | SLC8A1 (0.46) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4373721 | 0.85 | KDM4E (0.47) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4362108 | 0.84 | SLC8A1 (0.52) | SLC8A1MEN1KMT2AKDM4E | |
| SCHEMBL4360303 | 0.84 | HSPB1 (0.52) | SLC8A1MEN1KMT2A | |
| SCHEMBL4371977 | 0.84 | SLC8A1 (0.44) | SLC8A1MEN1KMT2AKDM4EPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7482340-B2 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2009-01-27 | — | — | US | disclosed |
| US-7425568-B2 | Compounds, which are potent inhibitors of Na+ /Ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2008-09-16 | — | — | US | disclosed |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | ORION CORPORATION (FI) | 2006-10-26 | — | — | US | disclosed |
| EP-1412343-B1 | COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORP (FI) | 2006-08-30 | — | — | EP | disclosed |
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | ORION CORPORATION (FI) | 2004-11-25 | — | — | US | disclosed |
| EP-1412343-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003006452-A1 | NEW COMPOUNDS, WHICH ARE POTENT INHIBITORS OF NA+/CA2+ EXCHANGE MECHANISM AND ARE USEFUL IN THE TREATMENT OF ARRHYTHMIAS | ORION CORPORATION (FI) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235905-A1 | Compounds, which are potent inhibitors of na+ / ca2+ exchange mechanism and are useful in the treatment of arrhythmias | CACNA1E, KCNN4, RYR2 | SLC8A1 40/4885MEN1 4334/4885KMT2A 1623/4885 |
| US-20060241147-A1 | Pyridine derivatives useful for inhibiting sodium/calcium exchange system | SLC8B1, CACNA1A, MCU | SLC8A1 5/4885MEN1 1596/4885KMT2A 4533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.